The content on this site is intended for healthcare professionals only
Prof Old Landgren speaks to ecancer at the 2019 ASH meeting in Orlando about some of the myeloma highlights from this year's conference.
In the newly-diagnosed setting, he mentions that the many new drugs are available provide an opportunity to cut down on treatments that can cause long-term toxicity. He adds that MRD testing can also help deliver deep and sustainable responses, ideally into MRD-negativity.
Prof Landgren goes on to discuss the potential impact of new insights into the biology of the disease that could even lead to curative outcomes.
Finally, he highlights one of the new bi-specific antibodies presented at the meeting that is achieving impressive outcomes.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
The current status of multiple myeloma diagnosis and treatment
